AI and Autonomy AI spots breast cancer risk years before diagnosis using routine mammograms The model evaluated the entire mammogram instead of focusing on a single characteristic such as breast density Joseph MortonJune 25, 2026
Sleep ProSomnus integrates sleep apnea monitoring device with MonitAir platform Obstructive sleep apnea affects millions of people and causes repeated interruptions in breathing during sleep Joseph MortonJune 18, 2026
Medical and Pharmaceutical Guardant Health launches multi-cancer blood test in Asia through Manulife partnership Cancer remains a leading cause of death across Asia, driving demand for early screening tools Joseph MortonMarch 18, 2026
Medical and Pharmaceutical Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation The FDA grants Breakthrough Device status to a limited group of technologies Joseph MortonFebruary 19, 2026
Medical and Pharmaceutical Lung Cancer Research Foundation expands 2025 grant program The partnership reflects a shared focus on improving survival by catching disease earlier Joseph MortonJanuary 6, 2026
Medical and Pharmaceutical McMaster surgeon develops AI tool to reduce invasive lung biopsies The technology uses an AI model trained on thousands of ultrasound scans Joseph MortonSeptember 25, 2025
Sleep Happy Ring gets FDA approval for sleep apnea diagnostics The sleep wearables market has been steadily expanding and will continue to do so Rowan DunneJune 19, 2025
Medical and Pharmaceutical IceCure Medical takes another step towards a full patent application in US IceCure continues expanding its intellectual property portfolio to strengthen its cryoablation platform Joseph MortonJune 10, 2025
Medical and Pharmaceutical QuidelOrtho seeks FDA approval to complete acquisition of LEX Diagnostics LEX Diagnostics develops molecular diagnostics to improve patient care by delivering clinical insights Joseph MortonJune 6, 2025
Medical and Pharmaceutical Checkpoint Therapeutics gets picked up by Sun Pharma, enjoys 60% share bump The deal could provide shareholders with an extra $0.70 per share if company's drug gains regulatory approval in Europe Joseph MortonMarch 10, 2025